MX2020012161A - Diagnostico mediante analisis de sangre. - Google Patents
Diagnostico mediante analisis de sangre.Info
- Publication number
- MX2020012161A MX2020012161A MX2020012161A MX2020012161A MX2020012161A MX 2020012161 A MX2020012161 A MX 2020012161A MX 2020012161 A MX2020012161 A MX 2020012161A MX 2020012161 A MX2020012161 A MX 2020012161A MX 2020012161 A MX2020012161 A MX 2020012161A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- chain
- determining
- level
- expression product
- Prior art date
Links
- 238000009534 blood test Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 3
- 210000002744 extracellular matrix Anatomy 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 abstract 2
- 102000004152 Bone morphogenetic protein 1 Human genes 0.000 abstract 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 abstract 2
- 102100033825 Collagen alpha-1(XI) chain Human genes 0.000 abstract 2
- 102100031502 Collagen alpha-2(V) chain Human genes 0.000 abstract 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 abstract 2
- 101000710623 Homo sapiens Collagen alpha-1(XI) chain Proteins 0.000 abstract 2
- 101000941594 Homo sapiens Collagen alpha-2(V) chain Proteins 0.000 abstract 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 abstract 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 abstract 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 abstract 2
- 102100032818 Integrin alpha-4 Human genes 0.000 abstract 2
- 102100025304 Integrin beta-1 Human genes 0.000 abstract 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 238000004393 prognosis Methods 0.000 abstract 2
- 206010002329 Aneurysm Diseases 0.000 abstract 1
- 102100031457 Collagen alpha-1(V) chain Human genes 0.000 abstract 1
- 101000941708 Homo sapiens Collagen alpha-1(V) chain Proteins 0.000 abstract 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101000935036 Ovis aries Integrin beta-1 Proteins 0.000 abstract 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 abstract 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 abstract 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente solicitud proporciona un método in vitro para determinar la degradación de la matriz extracelular (MEC) en un sujeto, método que consiste en determinar en una muestra aislada del sujeto el nivel de un producto de expresión de al menos un gen seleccionado del grupo formado por la cadena de colágeno tipo V alfa 1 (COL5A1), el factor de crecimiento transformante beta-1 (TGFB1), la subunidad de integrina alfa 4 (ITGA4), subunidad de integrina beta 1 (ITGB1), metaloproteinasa de matriz 2 (MMP2), metaloproteinasa de matriz 9 (MMP9) y proteína morfogenética ósea 1 (BMP1), determinándose opcionalmente el al menos un gen en combinación con uno o ambos de la cadena de colágeno tipo XI alfa 1 (COL11A1) y la cadena de colágeno tipo V alfa 2 (COL5A2), donde cuando el nivel del producto o productos de expresión es o son superiores a un valor de referencia, ello es indicativo de una MEC degradada. También se proporcionan métodos para el diagnóstico y pronóstico del cáncer y los aneurismas. Además, se proporcionan medios para determinar el nivel del producto de expresión de los genes en los métodos de diagnóstico o pronóstico antes mencionados, así como kits que contienen dichos medios.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2018/062897 WO2019219195A1 (en) | 2018-05-17 | 2018-05-17 | Diagnostic blood test |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012161A true MX2020012161A (es) | 2021-04-12 |
Family
ID=62217965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012161A MX2020012161A (es) | 2018-05-17 | 2018-05-17 | Diagnostico mediante analisis de sangre. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210102258A1 (es) |
| EP (1) | EP3794148B1 (es) |
| JP (2) | JP7437768B2 (es) |
| KR (1) | KR20210028149A (es) |
| CN (1) | CN112534066A (es) |
| AU (1) | AU2018423766A1 (es) |
| CA (1) | CA3100100A1 (es) |
| DK (1) | DK3794148T3 (es) |
| ES (1) | ES2931273T3 (es) |
| HU (1) | HUE059900T2 (es) |
| LT (1) | LT3794148T (es) |
| MX (1) | MX2020012161A (es) |
| PT (1) | PT3794148T (es) |
| RS (1) | RS63600B1 (es) |
| SI (1) | SI3794148T1 (es) |
| WO (1) | WO2019219195A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023550278A (ja) * | 2020-10-30 | 2023-12-01 | エフ． ホフマン－ラ ロシュ アーゲー | 胆管癌のマーカーとしてのｔｉｍｐ１ |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004018927D1 (de) | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
| ES2369667T3 (es) * | 2003-07-17 | 2011-12-02 | Pacific Edge Limited | Marcadores para la detección del cáncer gástrico. |
| ES2324435B1 (es) * | 2005-10-27 | 2010-05-31 | Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) | Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas. |
| WO2007068985A2 (en) * | 2005-12-16 | 2007-06-21 | Electrophoretics Limited | Diagnosis and prognosis of colorectal cancer |
| WO2011148983A1 (ja) * | 2010-05-25 | 2011-12-01 | 独立行政法人国立がん研究センター | 生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用 |
| WO2014004889A2 (en) * | 2012-06-27 | 2014-01-03 | Musc Foundation For Research Development | Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm |
| US20190127805A1 (en) * | 2016-03-15 | 2019-05-02 | Almac Diagnostics Limited | Gene signatures for cancer detection and treatment |
-
2018
- 2018-05-17 JP JP2020564408A patent/JP7437768B2/ja active Active
- 2018-05-17 CN CN201880093537.3A patent/CN112534066A/zh active Pending
- 2018-05-17 ES ES18726112T patent/ES2931273T3/es active Active
- 2018-05-17 RS RS20220872A patent/RS63600B1/sr unknown
- 2018-05-17 LT LTEPPCT/EP2018/062897T patent/LT3794148T/lt unknown
- 2018-05-17 PT PT187261128T patent/PT3794148T/pt unknown
- 2018-05-17 WO PCT/EP2018/062897 patent/WO2019219195A1/en active Application Filing
- 2018-05-17 HU HUE18726112A patent/HUE059900T2/hu unknown
- 2018-05-17 KR KR1020207034518A patent/KR20210028149A/ko not_active Application Discontinuation
- 2018-05-17 DK DK18726112.8T patent/DK3794148T3/da active
- 2018-05-17 AU AU2018423766A patent/AU2018423766A1/en active Pending
- 2018-05-17 MX MX2020012161A patent/MX2020012161A/es unknown
- 2018-05-17 EP EP18726112.8A patent/EP3794148B1/en active Active
- 2018-05-17 SI SI201830758T patent/SI3794148T1/sl unknown
- 2018-05-17 CA CA3100100A patent/CA3100100A1/en active Pending
-
2020
- 2020-11-17 US US16/950,825 patent/US20210102258A1/en active Pending
-
2023
- 2023-10-19 JP JP2023180226A patent/JP2024012341A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210028149A (ko) | 2021-03-11 |
| LT3794148T (lt) | 2022-10-10 |
| EP3794148B1 (en) | 2022-07-06 |
| HUE059900T2 (hu) | 2023-01-28 |
| SI3794148T1 (sl) | 2022-11-30 |
| JP2021530964A (ja) | 2021-11-18 |
| EP3794148A1 (en) | 2021-03-24 |
| CA3100100A1 (en) | 2019-11-21 |
| PT3794148T (pt) | 2022-09-27 |
| CN112534066A (zh) | 2021-03-19 |
| DK3794148T3 (da) | 2022-09-26 |
| RS63600B1 (sr) | 2022-10-31 |
| WO2019219195A1 (en) | 2019-11-21 |
| AU2018423766A1 (en) | 2020-12-24 |
| ES2931273T3 (es) | 2022-12-28 |
| JP7437768B2 (ja) | 2024-02-26 |
| US20210102258A1 (en) | 2021-04-08 |
| JP2024012341A (ja) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gardner et al. | Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts | |
| Vedula et al. | Different translation dynamics of β-and γ-actin regulates cell migration | |
| Zou et al. | Downregulation of dickkopf-1 enhances the proliferation and osteogenic potential of fibroblasts isolated from ankylosing spondylitis patients via the Wnt/β-catenin signaling pathway in vitro | |
| AU2007324705B2 (en) | Marker genes for use in the identification of chondrocyte phenotypic stability and in the screening of factors influencing cartilage production | |
| Rothdiener et al. | Human osteoarthritic chondrons outnumber patient‐and joint‐matched chondrocytes in hydrogel culture—Future application in autologous cell‐based OA cartilage repair? | |
| CN104937095A (zh) | 肾细胞群及其用途 | |
| Aguado et al. | Telomere length defines the cardiomyocyte differentiation potency of mouse induced pluripotent stem cells | |
| MX2020012161A (es) | Diagnostico mediante analisis de sangre. | |
| WO2022191149A1 (ja) | 毛包再生能を有する細胞の同定方法、及び毛包を再生するための組成物の評価方法 | |
| Rothweiler et al. | Predicting and promoting human bone marrow MSC chondrogenesis by way of TGFβ receptor profiles: toward personalized medicine | |
| NO314604B1 (no) | Deteksjon av syndekaninnholdet i biologisk materiale så som vevs- og kroppsv¶sker for angivelse av malign transformasjon av celler | |
| Menini et al. | MicroRNAs in Peri-implant Crevicular Fluid Can Predict Peri-implant Bone Resorption: Clinical Trial with a 5-Year Follow-up. | |
| WO2017126615A1 (ja) | 経時変化の情報を基に細胞を回収する方法およびシステム | |
| WO2011049439A1 (en) | Method for selecting bone forming mesenchymal stem cells | |
| Chen et al. | Bone marrow mesenchymal stem cell-derived extracellular vesicles containing miR-497-5p inhibit RSPO2 and accelerate OPLL | |
| CN105400895B (zh) | Shisa4基因作为椎间盘退行性病变诊治标志物的用途 | |
| US20230265493A1 (en) | Aorta-specific dna methylation patterns in cell-free dna from patients with bicuspid aortic valve-associated aortopathy | |
| CN108913654B (zh) | Hippo-YAP通路与Wnt通路相互作用在脂肪干细胞细胞谱命运选择中的用途 | |
| Pedersen et al. | Small leucine-rich proteoglycans in the vertebrae of Atlantic salmon Salmo salar | |
| Stephens | Development of a cell-based diabetic wound assay | |
| EP3696546A1 (en) | Method for selecting highly efficient stem cell, using protein marker grp78 | |
| Ness | Uveal Melanoma: Genetic and Epigenetic Characterisation | |
| Yang et al. | Circular RNA CircSLC8A1 contributes to osteogenic differentiation in hBMSCs via CircSLC8A1/miR‐144‐3p/RUNX1 in periprosthetic osteolysis | |
| Gil Vasquez et al. | Molecular phenotyping of colorectal neoplasia shows dynamic and adaptive cancer stem cell population admixture | |
| Culp et al. | Plasticity of CD44s expression during progression and metastasis of fibrosarcoma in an animal model system |